Many studies reported that meningiomas often express PD-L1, which correlates with higher grade and worse prognosis, and other immune checkpoints, such as TIM-3, NY-ESO-1, PD-1, PD-L2, B7-H3, and CTLA-4 [68–71]. This evidence concerns the gene CTLA4 and meningioma.